WallStSmart

Colgate-Palmolive Company (CL)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 129% more annual revenue ($46.72B vs $20.38B). SNY leads profitability with a 16.7% profit margin vs 10.5%. CL appears more attractively valued with a PEG of 3.26. CL earns a higher WallStSmart Score of 56/100 (C).

CL

Buy

56

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 4.7Quality: 3.3
Piotroski: 3/9

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLSignificantly Overvalued (-279.8%)

Margin of Safety

-279.8%

Fair Value

$22.51

Current Price

$85.49

$62.98 premium

UndervaluedFair: $22.51Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CL4 strengths · Avg: 8.8/10
Return on EquityProfitability
49.7%10/10

Every $100 of equity generates 50 in profit

Market CapQuality
$67.75B9/10

Large-cap with strong market position

Operating MarginProfitability
20.4%8/10

Strong operational efficiency at 20.4%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

CL4 concerns · Avg: 3.3/10
P/E RatioValuation
32.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
1.1%4/10

1.1% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.262/10

Expensive relative to growth rate

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CL

The strongest argument for CL centers on Return on Equity, Market Cap, Operating Margin.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : CL

The primary concerns for CL are P/E Ratio, EPS Growth, Piotroski F-Score. Debt-to-equity of 147.93 is elevated, increasing financial risk.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

CL profiles as a value stock while SNY is a mature play — different risk/reward profiles.

SNY carries more volatility with a beta of 0.36 — expect wider price swings.

SNY is growing revenue faster at 6.9% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

CL scores higher overall (56/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Colgate-Palmolive Company

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Colgate-Palmolive Company is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. It specializes in the production, distribution and provision of household, health care, personal care and veterinary products.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?